The US pharmaceutical industry’s commercial market has historically been the Wild West. Under a fee-for-service environment, physicians and their patients made many of the care decisions with few restrictions. However, the changing health care landscape, including the move to a value-based health care system, has changed the ability of manufacturers to drive growth through the lever of price.Read more
Filter by category or month:
Expanding Medical Affairs could help restore trust, demonstrate value of biopharma organizations and productsby Tom Yang, Principal, Monitor Deloitte, Deloitte Consulting, LLP
Within biopharmaceutical companies, Medical Affairs has often been seen as a necessity, but not necessarily core. This unit is typically neither responsible for the development nor commercialization of new drugs.
We see untapped value in Medical Affairs for biopharma, but few companies have been able to capture it. Here are three areas where Medical Affairs could enhance value for biopharma companies:
- Restoring trust: In an environment that has commonly grown skeptical of large biopharma companies,
When the music changes, so does the dance: Time for biopharma to get in step with value-based contractingby Joseph M. Coppola, Managing Director, Life Sciences Commercial and Market Access Practice Leader, Deloitte Consulting LLP
There is a well-known African proverb, “When the music changes, so does the dance.” I was thinking about this recently when I was a panelist on SAP’s Changing the Game in Life Sciences radio program, “Outcome-Based Pricing: Cure for An Ailing Healthcare Industry.” The moderator asked me for a quote that I felt best represented what was happening in the industry related to emerging pricing and payment models.Read more
Data and evidence were front and center at Academy Health’s recent National Health Policy Conference (NHPC). The event included a wide range of perspectives from the 700 attendees. Despite the diversity in the audience of health policymakers, legislators, practitioners, and academics, a common theme was that data and evidence should inform policy debates and decisions.Read more
In our last blog, we profiled several states that are transitioning their Medicaid programs to value-based care models. As we noted, some states are likely better prepared for the change than others. But how can states know if they are ready to “walk-the-walk” down the value-based care path?
Medicaid program leaders should first consider assessing readiness.Read more
Early-stage medtech venture investment is up, driven by digitally-enabled diagnostics. But is the market ready?by Sonal Shah, Senior Manager, Deloitte Center for Health Solutions, Deloitte Services LP
In my role with the Center for Health Solutions, I spend a fair amount of time researching technology and exploring the impact new medical devices could have on the health care sector. I generally don’t get much first-hand experience with medical devices. That recently changed.
When I told my primary care doctor about some odd sensations I had been feeling in my chest,Read more